MedPath
HSA Approval

APO-OLANZAPINE ODT ORALLY DISINTEGRATING TABLET 5MG

SIN14974P

APO-OLANZAPINE ODT ORALLY DISINTEGRATING TABLET 5MG

APO-OLANZAPINE ODT ORALLY DISINTEGRATING TABLET 5MG

March 30, 2016

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, ORALLY DISINTEGRATING

ORAL

Medical Information

N05AH03

olanzapine

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

Apotex Inc.

Active Ingredients

OLANZAPINE

5.0MG

Olanzapine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-OLANZAPINE ODT ORALLY DISINTEGRATING TABLET 5MG - HSA Approval | MedPath